Delivery of drugs to the brain is impeded by the activity of efflux pumps expressed by endothelial cells of brain vasculature. The ATP binding cassette (ABC) transporters, among which ABCB1/MDR1 P-glycoprotein and ABCC1/multidrug resistance-associated protein 1 are expressed in brain endothelial cells, participate in drug efflux properties of the blood-brain barrier (BBB). Searches of the EST (expressed sequence tags) database with the conserved ABC domain, conducted to identify other ABC transporters expressed in the BBB, recovered 15 ABC transporter sequences expressed in human brain cDNA libraries. One of these sequences, identical to ABCG2, was highly expressed in cultured human cerebromicrovascular endothelial cells and human brain tissue at both mRNA and protein levels. Overexpression of human ABCG2 in immortalized rat brain endothelial cells resulted in enhanced polarized abluminal to luminal transport of various substrates tested in the in vitro BBB model. Brain vessels extracted from tissue sections of nonmalignant human brain and glioblastoma tomors by laser capture microdissection microscopy and analyzed by real-time polymerase chain reaction showed higher expression of ABCG2 relative to ABCB1/MDR1 and ABCC1/MRP1. ABCG2 was up-regulated in both glioblastoma vessels and parenchymal tissue. These studies suggest a role for brain endothelial ABCG2 transporter in modulating drug delivery to the brain and in conferring drug resistance to glioblastomas.
Recently, a porcine homologue of the human breast cancer resistance protein (BCRP)/mitoxantrone resistance protein (MXR)/ABCG2 has been identified in CECs (19) . BCRP/MXR/ABCG2 has been discovered in ABCB1-and ABCC1-negative breast tumor cell lines selected for high resistance to mitoxantrone (20) (21) (22) (23) (24) . ABCG2 is located on human chromosome 4q22; the mRNA transcript of the gene is about 2.4 kb long and encodes a 72.1-kDa protein of 655 amino acids (21, 23) . ABCG2 has six predicted transmembrane domains and one ATP binding domain (21, 23) , which represent only "half" of the ABCB1/MDR1 structure characterized by 12 transmembrane domains and two ABCs (24, 25) . The initial in vitro studies suggested a role for the porcine homologue of ABCG2 (BMDP) in the active extrusion of daunorubicin (26) from brain endothelial cells. Initial phenotypic evaluation of Abcg2 −/− (bcrp1 −/− ) knockout mice revealed sensitivity to chlorophyll-derived dietary phototoxin (27) , but the functional role of ABCG2 in drug transport across the BBB has not been examined in these animals.
Deciphering the profile and activity of all expressed ABC transporters in BBB in both physiological and pathological conditions is of fundamental importance for predicting drug delivery and designing therapy for human brain diseases. For example, MDR of the most malignant primary brain tumor, glioblastoma multiforme (GBM) (28) , may be caused by increased expression of efflux transporters not only in tumor cells (3, 29) but also in tumor vessels, which would result in primary failure to deliver drugs to tumor cells.
In this study, a combination of bioinformatics and molecular and functional approaches was used to identify and characterize a subset of ABC transporters expressed in cultured human CECs and human vessels in vivo. The study reports the expression of ABCG2 in human BBB, provides evidence that ABCG2 participates in directional drug efflux in vitro, and describes up-regulation of ABCG2 in brain tumor vessels. This report also suggests that ABCG2 is an important component of drug efflux function of the BBB.
MATERIALS AND METHODS

Cell cultures
Primary human cerebromicrovascular endothelial cell (HCEC) cultures were isolated and maintained by using a modification (30) of procedures described originally by Gerhard and colleagues (31) . The cells were grown in medium containing 65% Dulbecco's modified Eagle's medium (DMEM) with a high glucose concentration (4500 mg/L) (Invitrogen, Carlsbad, CA), 10% FBS (HyClone, Logan, UT), 5% human serum (Sigma, St. Louis, MO), 20% murine melanoma cell-conditioned media, 5 µg/ml insulin, 5 µg/ml transferrin, 5 µg/ml selenium, and 10 µg/ml endothelial cell growth supplement (Collaborative Biomedical Products, Bedford, MA), as described previously (30) . Primary and propagated HCEC cultures were characterized for expression of endothelial and BBB markers as described previously (30) . Passages 3-6 of different HCEC isolations were used for experiments in this study.
Primary fetal (10-18 wk of gestation) human astrocyte (FHA) cultures were generously provided by Dr. J. Antel (Montreal Neurological Institute, Montreal, Quebec). These cultures were prepared by using a previously described procedure (32) . FHAs were grown in DMEM with a high glucose concentration (4500 mg/L) containing 10% FBS (HyClone) and 1X antibiotics (Invitrogen) in an atmosphere of 5% CO 2 /95% air at 37°C. More than 95% of cells in FHA cultures were immunopositive for glial fibrillary acidic protein (GFAP). Passages 3-6 of FHA cultures were used in this study.
Immortalized rat cerebromicrovascular endothelial cells (iRCECs) were established by transfecting primary rat CECs isolated as described previously (30) with a pSV3-neo vector (No. 37150; American Type Culture Collection [ATCC], Manassas, VA) encoding the Simian virus (SV) 40 large T antigen and the neomycin resistance gene, as described previously (33) . The cells were grown in complete medium 199 (M199; Sigma) containing 10% FBS (Multicell Premium, Wisent, Quebec, Canada), 0.5 g/L peptone, 4500 mg/L glucose, 1X basal medium Eagle (BME) amino acids, 1X BME vitamins, and 1X antibiotics (all obtained from Sigma) in an atmosphere of 5% CO 2 /95% air at 37°C.
Laser capture microscopy (LCM)-assisted microdissection of brain vessels
Frozen blocks of surgically removed and histopathologically assessed samples of nonmalignant brain tissue and GBM tumors were frozen-sectioned at 8-to 10-µm thickness via a cryostat (Jung CM3000, Leica, Nussloch, Germany Total RNA was isolated from pooled vessels captured from three or four sections (a total of 150-180 vessels) or parenchymal tissue using an Absolutely RNA Microprep Kit (Stratagene, La Jolla, CA) following the manufacturer's protocol. The RNA yield was about 0.05-0.1 µg.
Northern blot analysis
Total RNA was isolated from HCEC and iRCEC cultures with Trizol reagent (Invitrogen) according to the manufacturer's instruction. RNA pellets were dissolved in DEPC-treated Milli-Q distilled H 2 O at 55°C for 10 min and stored at −80°C until use. For Northern blot analysis, 5 µg of total RNA was resolved on 1.0% formaldehyde agarose gel and then blotted onto a piece of Immobilon-Ny + membrane (Millipore, Bedford, MA) as described before (34) . DNA probes for ABCG2 (EST56968/ATCC No. 150857/GenBank Accession No. AA349979/AY288307) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were labeled with [α-32 P]dCTP by random priming. The blots were prehybridized for 4 h at 55°C and then hybridized with labeled probes overnight at 55°C in a hybridization chamber (Robbins Scientific, Sunnyvale, CA). The blots were then washed as described previously (34) and were exposed to X-ray film (Kodak, Rochester, NY) overnight at −80°C. ABCG2 expression was normalized against GAPDH cDNA probe hybridization.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
For the RT reaction, total RNA (0.5 µg of RNA isolated from cultured cells and brain tissues or 0.05-0.1 µg of RNA from LCM-captured samples) was mixed with 1 µg of oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers, heated for 10 min at 70°C, and then cooled gradually to 4°C. First-strand cDNA synthesis (reverse transcription) was carried out (20-µl reaction) as described before (35) , and 5 µl of cDNA was used in each subsequent PCR reaction. Specific primers for human ABCG2, ABCB1/MDR1, ABCC1/MRP1, GAPDH, and β-actin were designed according to published sequences from GenBank (Table 1) . PCR amplifications were performed in a final volume of 50 µl as described elsewhere (35) . All amplifications were done with a denaturation step at 94°C for 30 s, an annealing step at 55°C for 45 s, and a polymerization step at 72°C for 45 s. All PCR reactions were analyzed as described previously (35) .
Real-time quantitative PCR (Q-PCR)
The general procedures used for real-time Q-PCR were as described previously (36) . SYBR Green PCR Core Reagents kits and an ABI Prism 7700 Sequence Detector System (Applied Biosystems, Foster City, CA) were used to conduct Q-PCR reactions. An increase in the fluorescence of the reporter dye, SYBR green, during Q-PCR is due to the SYBR green binding to double-stranded DNA.
First-strand cDNA was synthesized from total RNA isolated from HCECs, FHAs, human brain tissue biopsy specimens, and LCM-captured tissues as described above. The Q-PCR primers for human ABCG2, ABCB1/MDR1, ABCC1/MRP1, β-actin, and GAPDH were designed according to the published sequences from GenBank and synthesized by Applied Biosystems (Table 1) . For each amplicon of Q-PCR, the amount of a target gene and an endogenous reference (β-actin or GAPDH) was determined from a standard curve generated by serial dilutions ranging from 1:10 to 1:1000 of β-actin or GAPDH. The reference gene and the target gene were amplified in duplicate during each experiment, and the amount of a target gene was normalized to the reference. Before amplification, samples were incubated at 50°C for 2 min (AmpErase UNG Incubation) and 95°C for 15 min (AmpliTaq Gold activation). Each amplification cycle consisted of denaturation for 15 s at 95°C and annealing/extension for 1 min at 60°C. The Q-PCR was conducted for 40 cycles. To confirm that the expected product was generated and to distinguish specific from nonspecific products and primer-dimers, a melting curve analysis was performed after amplification by maintaining the temperature at 70°C for 30 s, followed by a gradual increase in temperature to 98°C at a rate of 0.1°C/s, with the signal acquisition mode set at stepacquisition mode. The data were analyzed as described previously (37) .
Western blot analysis
Equal amounts (25 µg) of protein from each HCEC and FHA culture were resolved by 9% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The gels were soaked for 15 min in a transfer buffer containing 25 mM Tris base, 192 mM glycine, and 10% methanol, and the proteins in the gels were then transferred to a piece of Immobilon-P membrane (Millipore) using a Hoefer apparatus (Amersham Pharmacia Biotech, Montreal, PQ, Canada). All subsequent procedures were performed according to an Amersham Pharmacia ECL Plus protocol (Amersham Pharmacia Biotech). Membranes were probed either with a 1:200 dilution of a primary mouse monoclonal anti-human ABCG2 (sc-18841) antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by a 1:3000 dilution of a secondary goat anti-mouse IgG-horseradish peroxidase antibody (Santa Cruz Biotechnology), or with a 1:100 dilution of a primary mouse monoclonal anti-BCRP (BXP-21) antibody from ID Laboratory (London, Ontario, Canada) followed by a 1:1000 dilution of a secondary goat anti-mouse IgG-HRP A4416 antibody (Sigma). The blots were also probed with a primary mouse monoclonal anti-β-actin antibody A5441 (1:5000 dilution) (Sigma) and a secondary antibody A4416 (1:1000 dilution) (Sigma) to control for equal loading of protein samples. ECL Plus reagents (Amersham Pharmacia Biotech) were applied to the blots, which were exposed to autoradiography films (Kodak) for 30 s to 3 min.
Immunohistochemistry
Immunostaining of tissue sections with an endothelial marker, factor VIII-related antigen (von Willebrand factor; FVIII-rAg), was carried out as described previously (30) to visualize brain vessels. Immunohistochemistry for ABCG2 was carried out in brain tissue sections washed three times with 0.2 M phosphate buffer (pH 7.3) containing 0.1% Triton X-100. Sections were preblocked with a universal blocking solution (Dako Diagnostics, Mississauga, ON, Canada) for 20 min at room temperature. The blocking solution was removed without washing, and the sections were first incubated with a monoclonal mouse anti-human ABCG2 antibody (1:100 dilution; Santa Cruz Biotechnology) for 18 h at 4°C and then were washed three times (5 min/wash) in 0.2 M phosphate buffer (pH 7.3) and then incubated with a Texas Red-conjugated goat anti-mouse IgG antibody (1:200 dilution) (Molecular Probes, Eugene, OR) for 2 h. Slides were then washed and were dehydrated in ethanol (5 min each in 70%, 96% and 100% ethanol), followed by two 5-min treatments with xylene. The slides were then air-dried, covered with a mounting medium (Dako Diagnostics), covered with coverslips, and examined under a fluorescent Olympus IX-50 microscope (Olympus America, Lake Success, NY). In control slides, the primary antibody was either omitted or replaced with an anti-human IgG antibody.
cDNA cloning and transfection
Full-length cDNA for the human ABCG2 gene (hABCG2) was cloned into a pcDNA3.1 vector by using Elongase (Invitrogen) amplification of cDNA samples prepared from primary HCEC cultures according to the manufacturer's instructions. The construct was sequenced to confirm sequence accuracy. The ABCG2 construct or the empty vector was transfected into iRCECs by using SuperFect reagent (Qiagen, Mississauga, ON, Canada) according to the manufacturer's instruction. Clones expressing hABCG2 were selected in the presence of 500 µg/ml Geneticin (Invitrogen) and used in drug uptake and drug transport assays.
Drug uptake and transport assays
For drug uptake assays, 80,000 cells/ml were plated in 24-well plates and grown until 90% confluent. In preliminary experiments, the selection drug, Geneticin, interfered with the uptake of rhodamine 123 (R123) (Sigma). In all subsequent drug uptake and transport experiments, cells were plated and maintained in Geneticin-free media. Uptake assays were performed in phenol red-free M199 medium. Fluorescent drugs, mitoxantrone, fluorescein, or R123, were added to the cells at final concentrations of 20 µM, 75 µM, and 15 µM, respectively, for 1 h at 37°C. Cells were then washed twice with phenol red-free HBSS (Sigma), 1 ml of phenol red-free M199 medium (Sigma) was added to each well, and plates were scanned from the bottom in a microplate fluorescence reader FL600 (Bio-Tek Instruments, Winooski, VT) using 485/20 nm excitation and 530/25 nm emission wavelengths for R123 and fluorescein, and 485/20 nm excitation and 645/40 nm emission wavelengths for mitoxantrone (38) .
Drug transport assays were performed by using an in vitro compartmentalized BBB model as described previously (33, 39, 40) . iRCECs (80,000 cells/ml) were plated in tissue culture inserts (Becton, Dickinson Labware, Bedford, NJ) with 1-µm pore size in the absence of Geneticin. The inserts were placed into wells of a 12-well plate (Becton, Dickinson Labware) containing 2 ml of a (1:1 v/v) rat astrocyte-conditioned medium (1% FBS, high glucose concentration DMEM, conditioned for 72 h) and iRCEC medium. Barrier integrity was assessed by measuring transendothelial electrical resistance (TEER) with an Endohm electrical resistance apparatus (World Precision Instruments, Sarasota, FL). All transport experiments were performed in a transport buffer (HBSS containing 5 mM glucose, 10 mM HEPES pH 7.4, and 0.05% BSA) after equilibrating the cells for 30 min at 37°C. Mitoxantrone, fluorescein, and R123 were added to either the upper (apical to basolateral transport) or the lower (basolateral to apical transport) compartment at final concentrations of 20 µM, 75 µM, and 15 µM, respectively. Aliquots from the opposite chamber were collected at various intervals during a 120-min period and scanned in a microplate fluorescence reader FL600 (Bio-Tek Instruments) as described above. Clearance values were determined by using previously described protocols (33, 40) .
RESULTS
ABC transporter EST sequences expressed in human brain cDNA libraries
To identify a subset of ABC transporter genes expressed in human brain cDNA libraries, we conducted searches of the expressed sequence tags database (dbEST) and analyses with the conserved ABC. In addition to ABCB1/MDR1 and ABCC1/MRP1, 15 other ABC transporter EST sequences were identified in human brain cDNA libraries including members from ABCA subfamily (A1, A2, A5), ABCB subfamily (B4, B6, B7, B8, B9), ABCC subfamily (C4, C5), ABCF subfamily (F1, F2), and ABCG subfamily (G1, G2, G4). These EST clones were then purchased from ATCC, specific primers were designed for each clone according to the published EST sequences from dbEST and GenBank, and the expression of these genes in HCEC was determined by semiquantitative RT-PCR and Northern blot analyses. Three genes (ABCG2, ABCB9, and ABCC5) were detected in HCECs by RT-PCR and one (subsequently found to correspond to ABCG2) by Northern blot analysis.
The ABC transporter EST sequence detected in HCECs by both RT-PCR and Northern blot was dbEST ID 991288; EST name 56968; GenBank Accession No. AA349979; ATCC No. 150857. Sequence analysis of this clone revealed that it carries an insert of 1689 bp with a 1626-bp coding region that encodes 542 amino acids including an ATP binding domain, but it lacks the 5'-end sequence of the gene (GenBank Accession No. AY288307). By using this EST cDNA as a probe, a 2.2-kb cDNA fragment was recovered from a lambda ZAP II cDNA library of primary HCECs developed in the laboratory (41, 42) . This fragment contained a full-length coding region of 1965 bp encoding a 655 amino acid polypeptide that corresponded to ABCG2/BCRP (GenBank Accession No. AY289766).
ABCG2 expression in brain cells and tissues
In subsequent studies, ABCG2 mRNA expression was analyzed in HCECs, FHAs, and whole human brain tissue by using RT-PCR and real-time Q-PCR. ABCG2 protein expression was determined by Western blot and immunohistochemistry. ABCG2 mRNA was detected in four tested samples of whole human brain (data not shown), in each of six HCEC cultures derived from different patients (Fig. 1A) , and in each of five FHA isolations (Fig. 1B) tested. Expression of ABCG2 protein was detected in both HCEC and FHA cultures by Western blot analyses (Fig.  1C) using two different primary ABCG2 antibodies, sc-18841 from Santa Cruz Biotechnology (Fig. 1C) and BXP-21 from ID Laboratory (data not shown), both of which recognized a common 72-kDa protein band (Fig. 1C) . The other strong band observed on Western blots at about 150 kDa (Fig. 1C) likely represents ABCG2 homo-or heterodimers.
Immunohistochemistry performed with sections of human brain, using the same primary antibodies as in Western blot analyses, showed strong staining of vascular structures and diffuse, weaker staining of perivascular tissues for ABCG2 (Fig. 1D) . Staining was absent in sections in which the primary ABCG2 antibody was replaced with an anti-IgG antibody (Fig. 1E) .
Comparative expression analyses of ABCG2 and two other ABC transporters previously characterized in the BBB, ABCB1/MDR1 and ABCC1/MRP1, were conducted for HCECs, FHAs, and whole human brain by using real-time Q-PCR (Fig. 2) . The expression was normalized to that of β-actin in the same samples. ABCC1/MRP1 expression was abundant in HCECs ( Fig. 2A) and FHAs (Fig. 2B) , consistent with previous reports of ABCC1/MRP1 upregulation in cultured CECs (13, 14, 16) . Similar expression levels of ABCG2 and ABCB1/MDR1 were detected in HCECs, whereas in FHAs the ABCG2 expression was three-to fourfold lower compared with ABCB1/MDR1 expression. In whole brain homogenates, ABCG2 and ABCC1/MRP1 were expressed at similar and relatively higher levels than was ABCB1/MDR1 (Fig. 2C) .
Functional characterization of ABCG2 in CECs
Functional characterization of ABCG2 was performed in CECs transfected with ABCG2. Because stable overexpression of ABCG2 gene could not be achieved in primary HCECs, rat brain endothelial cells immortalized by a stable transfection of SV40 large T antigen (iRCECs) were used in these studies. Northern blot analysis with a 32 P-labeled hABCG2 cDNA probe (EST56968/ATCC No. 150857/GenBank Accession No. AA349979/AY288307) showed strong hybridization with HCECs (Fig. 3A) , and no hybridization with iRCECs (Fig. 3A) . The length of the ABCG2 mRNA transcript detected was about 2.4 kb (Fig. 3A) .
The full-length coding region of hABCG2 was cloned into a pcDNA3.1 expression vector (Invitrogen) and sequenced for accuracy. The hABCG2 construct or an empty vector was transfected into iRCECs, and clones expressing hABCG2 were selected with G418/neomycin (500 µg/ml Geneticin). The expression of hABCG2 in selected clones was confirmed by RT-PCR using a primer in the promoter region of the vector (5′-TAATACGACTCACTATAGGG-3′) and a primer located in the cloned hABCG2 (5′-CGAGGCTGATGAATGGAGAAG-3′) (Fig. 3B) . Only clones demonstrating high and stable hABCG2 expressions (e.g., clone 2; Fig. 3B ) were used for subsequent drug uptake and transport assays. iRCECs express both Abcb1 and Abcc1, and the expression of these transporters was not affected by hABCG2 transfection (data not shown).
Drug uptake assays showed that hABCG2-expressing iRCECs accumulated about 37%, 33%, and 55% less mitoxantrone, R123, and fluorescein, respectively (Fig. 3C ) than did either nontransfected or empty vector-transfected iRCECs. An in vitro BBB model described previously (33, 39, 40 ) was used to assess directional drug transport across the hABCG2-expressing iRCEC monolayer. Luminal to abluminal (top-to-bottom) transport of mitoxantrone (Fig. 4A), R123 (Fig. 4B) , and fluorescein (Fig. 4C) was significantly reduced across hABCG2-transfected iRCECs compared with empty-vector transfected iRCECs. In contrast, abluminal to luminal (bottom-to-top) transport of all three drugs was increased across hABCG2-transfected iRCEC monolayers compared with empty-vector transfected iRCECs (Fig. 4) .
ABCG2 expression and regulation in brain vessels in vivo
To characterize the expression profile of ABCG2 in brain vessels in pathological conditions, LCM microscopy was used to extract vessels from frozen sections of surgically removed nonmalignant human brain lesions and GBM. Vessels in tissue sections were stained with a fluorescent dye-labeled lectin, UEA-I, that specifically binds to fucose residues in human brain endothelia (43) (Fig. 5) . UEA-I staining of brain vessels was more compatible with LCM than FVIII-rAg immunostaining because of a short staining time (2-5 min) and high RNA quality. GBM sections stained with UEA-I showed a higher density of microvessels (Fig. 5B ) compared with nonmalignant brain (Fig. 5A) , consistent with previous reports (28, 29) . Figure 5C depicts results of LCM capture of selected UEA-I-stained vessel from tissue sections. The morphology of captured vessels was well preserved and relatively free of contaminating surrounding tissue. Captured samples were enriched in FVIII-rAg mRNA and had minimal GFAP contamination by RT-PCR (data not shown), which suggests that the captured material represents the neurovascular unit tissue rather than a pure endothelial cell population.
Expression of ABCG2 in LCM-captured vessels or perivascular parenchyma was determined by RT-PCR (Fig. 6A ) and real-time Q-PCR (Fig. 6B ) using β-actin and GAPDH as internal controls, respectively. In nonmalignant brain, ABCG2 expression was similar in both vascular and parenchymal tissues (Fig. 6A and B) . In GBM, ABCG2 mRNA expression was highly upregulated in both vessels (8.4-fold) and parenchyma (2.8-fold) (Fig. 6A and B) compared with expression in nonmalignant brain. Interestingly, the pattern of ABCC1/MRP1 mRNA expression in the same samples showed an opposite trend ( Fig. 6A and B) : higher expression in control vessels compared with GBM vessels. Up-regulation of ABCC1/MRP1 was observed in parenchyma of GBM compared with control brain (Fig. 6A and B) . Expression of ABCB1/MDR1 was not detectable by RT-PCR or Q-PCR in either brain vessels or parenchyma extracted by LCM (data not shown).
DISCUSSION
The goal of the studies described in this manuscript was to identify and characterize a subset of ABC transporters expressed at the BBB by using a combination of bioinformatics and molecular and functional approaches. The ABC motif characteristic of the ABC transporter family was identified in 15 EST clones from human brain cDNA libraries (41) . One of these clones, identical to ABCG2, was also abundantly expressed in primary human brain endothelial cells in vitro and human brain vessels in vivo (41, 42) . Overexpression and pharmacological studies with an in vitro model of the BBB then showed that ABCG2 is involved in a polarized efflux of drug substrates. ABCG2 up-regulation was detected in brain vessels of GBM, which suggested that the transporter may limit access of chemotherapeutics to brain tumors.
The impact of BBB efflux pumps on brain physiology and pathology can be assessed only by monitoring the expression and functional activity of a full complement of transporters and efflux pumps in brain endothelial cells. dbEST searches recently contributed to identification of 21 new human ABC transporter genes (44) . In this study, tissue-specific dbEST searches identified 15 ABC-containing genes in human brain cDNA libraries. One of these genes was highly expressed in HCECs (41) and was subsequently identified as ABCG2 (10, 11, 42) . Two other reports recently described the expression of ABCG2 in the BBB. Eisenblatter and Galla (19) discovered a new porcine sequence with 84% identity to the human BCRP/ABCG2 gene after screening a subtracted cDNA library of porcine capillary brain endothelial cells grown in the presence or absence of hydrocortisone. They also demonstrated the expression of this gene in various porcine tissues including brain, freshly isolated brain capillaries and cultured brain endothelial cells (19, 26) . A report by Cooray and colleagues (45) confirmed the presence of both ABCG2 mRNA and protein in human brain with predominant localization in microvessel endothelium. Studies reported here confirm prior work by demonstrating ABCG2 mRNA and protein expression in human CEC in vitro and in human brain vessels in situ. In addition, the first quantitative analyses of ABCG2 expression in endothelial and astrocytic compartments of human brain and an initial characterization of functional capacity of this transporter were conducted. ABCG2 mRNA expression level in HCECs was similar to that of ABCB1/MDR1, whereas in FHAs ABCB1/MDR1 was five times more abundant than ABCG2, which indicated a specific role for ABCG2 in the BBB. The relative abundance of ABCC1/MRP1 compared with ABCB1/MDR1 and ABCG2 in both cultured HCECs and FHAs but not in whole brain tissue suggests that ABCC1/MRP1 up-regulation is likely an artifact of cell culture conditions. Previous studies have indicated that ABCC1/MRP1 is up-regulated in cultured CECs compared with freshly isolated brain microvessels (13) .
Functional studies demonstrated that hABCG2 transfected into iRCECs reduced cellular uptake of a relatively selective ABCG2 substrate, mitoxantrone, as well as that of R123 and fluorescein (20) (21) (22) (23) (24) . hABCG2 transfected into iRCECs enhanced polarized drug transport across cell monolayers, which resulted in reduced drug influx from the luminal compartment and increased drug efflux from the abluminal compartment of the in vitro BBB model. The findings imply that transfected hABCG2 translates into an active protein capable of directional substrate efflux. Consistent with these findings, immunofluorescence studies of human brain tissue sections (45) described predominant ABCG2 localization at the luminal surface of microvessel endothelium.
Collectively, these studies suggest that ABCG2 is an important component of BBB efflux activity.
The substrate specificity and transport activity of ABCG2 can be influenced by gene polymorphism (46) (47) (48) . It has been reported that the wild-type ABCG2 (arginine at amino acid number 482), in contrast to ABCG2 carrying a single base polymorphism (threonine or glycine at number 482), is not capable of transporting R123 in drug-resistant cancer cell lines (48) . Although the ABCG2 gene cloned in this study encodes a wild-type protein (Arg482), the transfected protein appears to be capable of transporting R123, provided that the cells were grown and maintained in G418-free conditions for at least one passage. A recent study (47) demonstrated that R123, mitoxantrone, and doxorubicin inhibit methotrexate transport by wildtype ABCG2 protein (Arg482) reconstituted in vitro in plasma membrane vesicles. The observed discrepancies in ABCG2 substrate profiles influenced by gene polymorphism can be attributed to different cell types or model systems and different experimental conditions (e.g., presence or absence of selection drugs) used in these studies. Homo-and/or heterodimerization of ABCG2, deemed a "half" transporter, may also be important for activity modulation or substrate specificity (21, 24) . In general, the findings from functional studies reported in this study are consistent with the described substrate profile of ABCG2 in other cells types (24) .
ABCG2 shares many similarities with ABCB1/MDR1, including functional roles in MDR to cancer chemotherapy and the ability of overexpressed genes to confer drug resistance in cellular models (6, 11, 24, 25) . Gene knockout studies clearly support a major role for ABCB1/MDR1 (6, 14) and a minor role for ABCC1/MRP1 in BBB drug efflux (6, 11, 17) . The relative importance of ABCG2 in BBB drug efflux in vivo is difficult to assess, because most known ABCG2 substrates are also substrates for either ABCB1/MDR1 or ABCC1/MRP1 (24) . Brain uptake and toxicity for most of these substrates are markedly enhanced in Abcb1a (mdr1a −/− ) and Abcb1a/b (mdr1a/b −/− ) (6, 11, 14) knockout mice, which suggests that ABCG2 cannot compensate for a loss of ABCB1/MDR1 and that its role in xenobiotic efflux in vivo may be minor.
However, the following must be considered when data obtained in Abcb1-deficient animals are extrapolated to other efflux transporters, and, specifically, ABCG2: 1) ABCG2 may be critically important in the BBB efflux of a smaller number of selective substrates; 2) gene polymorphism described in both ABCB1/MDR1 (25) and ABCG2 genes (46) likely results in an individualized "profile" of drug sensitivity, in which either transporter can become functionally predominant; 3) species differences in BBB function have been described (49) and data obtained in Abcb1 knockout mice may not be directly translated to other species; 4) pathways involved in transcriptional, translational, and post-translational regulation of ABC transporters in BBB endothelium are obscure, and various physiological or pathological conditions may shift the functional importance in favor of a specific transporter. Because drug pharmacokinetics is also affected by the substrate affinity, multiple transporters at BBB may operate synergistically over a range of substrate concentrations. Although recently generated Abcg2 −/− (bcrp1 −/− ) knockout mice were found to be sensitive to chlorophyll-derived dietary phototoxin and developed protoporphyria (27) , neurotoxic effects of ABCG2 substrates have not been reported. Another confounding factor in dissecting the specific role of ABCG2 in the BBB in vivo is the expression of the Abcg3 gene, highly homologous to Abcg2, in the mouse but not in the human genome (50) . Nevertheless, because of several limitations including reduced complexity, lack of factors influencing drug pharmacodynamics (e.g., flow, organ clearance), and potential phenotypic changes caused by culture conditions, in vitro models alone are unlikely to provide definitive answers on the relative importance of ABCG2 in drug transport across the BBB.
To examine changes in ABCG2 expression in pathological states in vivo, we compared vessels extracted in situ from GBM and nonmalignant brain tissue. GBM is the most common primary brain tumor highly resistant to chemotherapy (3, 28, 29) . Both ABCB1/MDR1 and ABCC1/MRP1 have been implicated in the drug resistance of the GBM on the basis of immunohistochemical and biochemical studies in whole tumor tissues (28, 29, 52) . These studies indicated that various members of the ABCC/MRP family are strongly expressed in glioblastoma cell lines (3) and various types of brain tumors (29) , whereas ABCB1/MDR1 was variably present but not up-regulated in GBM (29) . We hypothesized that MDR of GBM may in part result from increased expression of ABC transporters at the blood-tumor barrier. Although the blood-GBM barrier is generally considered "modified" when compared with the physiological BBB (51), it exhibits sufficient tightness to limit diffusion of chemotherapeutics and requires aggressive osmotic (52) or chemical (51) disruption in GBM treatment protocols. Microvessels from the GBM and nonmalignant brain tissue sections were extracted by using an LCM technique that enables capture of specific cell populations from morphologically diverse tissues compatible with subsequent molecular fingerprinting. ABCG2 was markedly up-regulated in both vessels and parenchyma of GBM compared with nonmalignant brain, whereas ABCC1/MRP1 was up-regulated in parenchyma of GBM, consistent with previous reports (3, 29) , but was down-regulated in GBM vessels. The data suggest that the drug resistance phenotype of GBM is likely regulated by combined changes in the expression of specific drug transporters in both tumor vessels and parenchyma. Similarly, overexpression of several MDR genes and proteins was detected in brain endothelial cells derived from the temporal lobe of patients with refractory epilepsy (4). ABCB1/MDR1 expression was not detectable in LCMcaptured samples, most likely because of low total RNA yields or specific mRNA instability. Earlier studies suggested that ABCB1/MDR1 may not be an important player in pharmacoresistance of the GBM (53) . In contrast, ABCG2 likely contributes to drug resistance of the GBM and may be a new target for modulating the vascular barrier and improving the efficacy of chemotherapy.
Drug delivery to the brain remains one of the most perplexing challenges facing the pharmaceutical industry. The identification of expression and functionality of ABC transporters in the BBB, including ABCG2, will help understand the biodistribution and pharmacokinetics of brain-targeted drugs and develop approaches to overcome the BBB. General principles of the approach described here are applicable to many other fields, including cancer chemotherapy, drug development, and vascular diseases in general. 
*RT-PCR using these primers generated a 203-bp fragment for ABCG2, a 295-bp fragment for MDR1, a 389-bp fragment for MRP1, a 504-bp fragment for β-actin, and 145-bp fragment for GAPDH. 
